Cargando…
Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
The Omicron BA.1 (B.1.1.529) SARS-CoV-2 variant is characterized by a high number of mutations in the viral genome, associated with immune escape and increased viral spread. It remains unclear whether milder COVID-19 disease progression observed after infection with Omicron BA.1 in humans is due to...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295819/ https://www.ncbi.nlm.nih.gov/pubmed/35787236 http://dx.doi.org/10.1080/22221751.2022.2095932 |
_version_ | 1784750134923362304 |
---|---|
author | Rissmann, Melanie Noack, Danny van Riel, Debby Schmitz, Katharina S. de Vries, Rory D. van Run, Peter Lamers, Mart M. Geurts van Kessel, Corine H. Koopmans, Marion P. G. Fouchier, Ron A. M. Kuiken, Thijs Haagmans, Bart L. Rockx, Barry |
author_facet | Rissmann, Melanie Noack, Danny van Riel, Debby Schmitz, Katharina S. de Vries, Rory D. van Run, Peter Lamers, Mart M. Geurts van Kessel, Corine H. Koopmans, Marion P. G. Fouchier, Ron A. M. Kuiken, Thijs Haagmans, Bart L. Rockx, Barry |
author_sort | Rissmann, Melanie |
collection | PubMed |
description | The Omicron BA.1 (B.1.1.529) SARS-CoV-2 variant is characterized by a high number of mutations in the viral genome, associated with immune escape and increased viral spread. It remains unclear whether milder COVID-19 disease progression observed after infection with Omicron BA.1 in humans is due to reduced pathogenicity of the virus or due to pre-existing immunity from vaccination or previous infection. Here, we inoculated hamsters with Omicron BA.1 to evaluate pathogenicity and kinetics of viral shedding, compared to Delta (B.1.617.2) and to animals re-challenged with Omicron BA.1 after previous SARS-CoV-2 614G infection. Omicron BA.1 infected animals showed reduced clinical signs, pathological changes, and viral shedding, compared to Delta-infected animals, but still showed gross- and histopathological evidence of pneumonia. Pre-existing immunity reduced viral shedding and protected against pneumonia. Our data indicate that the observed decrease of disease severity is in part due to intrinsic properties of the Omicron BA.1 variant. |
format | Online Article Text |
id | pubmed-9295819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-92958192022-07-20 Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters Rissmann, Melanie Noack, Danny van Riel, Debby Schmitz, Katharina S. de Vries, Rory D. van Run, Peter Lamers, Mart M. Geurts van Kessel, Corine H. Koopmans, Marion P. G. Fouchier, Ron A. M. Kuiken, Thijs Haagmans, Bart L. Rockx, Barry Emerg Microbes Infect Coronaviruses The Omicron BA.1 (B.1.1.529) SARS-CoV-2 variant is characterized by a high number of mutations in the viral genome, associated with immune escape and increased viral spread. It remains unclear whether milder COVID-19 disease progression observed after infection with Omicron BA.1 in humans is due to reduced pathogenicity of the virus or due to pre-existing immunity from vaccination or previous infection. Here, we inoculated hamsters with Omicron BA.1 to evaluate pathogenicity and kinetics of viral shedding, compared to Delta (B.1.617.2) and to animals re-challenged with Omicron BA.1 after previous SARS-CoV-2 614G infection. Omicron BA.1 infected animals showed reduced clinical signs, pathological changes, and viral shedding, compared to Delta-infected animals, but still showed gross- and histopathological evidence of pneumonia. Pre-existing immunity reduced viral shedding and protected against pneumonia. Our data indicate that the observed decrease of disease severity is in part due to intrinsic properties of the Omicron BA.1 variant. Taylor & Francis 2022-07-17 /pmc/articles/PMC9295819/ /pubmed/35787236 http://dx.doi.org/10.1080/22221751.2022.2095932 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Coronaviruses Rissmann, Melanie Noack, Danny van Riel, Debby Schmitz, Katharina S. de Vries, Rory D. van Run, Peter Lamers, Mart M. Geurts van Kessel, Corine H. Koopmans, Marion P. G. Fouchier, Ron A. M. Kuiken, Thijs Haagmans, Bart L. Rockx, Barry Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters |
title | Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters |
title_full | Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters |
title_fullStr | Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters |
title_full_unstemmed | Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters |
title_short | Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters |
title_sort | pulmonary lesions following inoculation with the sars-cov-2 omicron ba.1 (b.1.1.529) variant in syrian golden hamsters |
topic | Coronaviruses |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295819/ https://www.ncbi.nlm.nih.gov/pubmed/35787236 http://dx.doi.org/10.1080/22221751.2022.2095932 |
work_keys_str_mv | AT rissmannmelanie pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT noackdanny pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT vanrieldebby pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT schmitzkatharinas pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT devriesroryd pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT vanrunpeter pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT lamersmartm pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT geurtsvankesselcorineh pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT koopmansmarionpg pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT fouchierronam pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT kuikenthijs pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT haagmansbartl pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters AT rockxbarry pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters |